Skip to content

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Double-masked Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Multi-center Study, in Comparison to 0.1% Sodium Hyaluronate Ophthalmic Solution) - Phase III Confirmatory Study -

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01240382
Enrollment
332
Registered
2010-11-15
Start date
Unknown
Completion date
Unknown
Last updated
2014-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Brief summary

To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6 times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate ophthalmic solution (0.1% HA) (one drop at a time, 6 times daily, 4 weeks topical administration), is at least non-inferior in the change in fluorescein staining score, and is superior in the change in Rose bengal score, in a multicenter, double-masked, parallel-group comparison study. Safety profile will likewise be compared.

Interventions

DRUG3% DE-089 ophthalmic solution

Sponsors

Santen Pharmaceutical Co., Ltd.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum

Inclusion criteria

* Those who show: * Keratoconjunctival disorder confirmed with vital dye staining * Abnormal Schirmer score results

Exclusion criteria

* Eye disease that needs therapy other than that for dry eye * Those who need to wear contact lenses during the clinical study

Design outcomes

Primary

MeasureTime frameDescription
Mean Change in Fluorescein Staining Score From BaselineBaseline and 4-week (discontinued (LOCF))Fluorescein staining was scored according to the protocol by Shimmura et al. The cornea was divided into 3 equal zones: upper, middle, and lower. Each zone had a staining score ranging between 0 and 3 points, with minimum and maximum total staining scores ranging between 0 and 9 points. 0 is better. The degree of staining with Fluorescein dyes was scored as follows: 0 = no staining, 1= staining of less than half of the area, 2= staining of more than half of the area, 3= staining in the whole area.
Mean Change in Rose Bengal Staining Score From BaselineBaseline and 4-week (discontinued (LOCF))Rose bengal staining were scored according to the protocol by Shimmura et al. The ocular surface was divided into 5 zones: nasal and temporal conjunctival, and upper, middle, and lower corneal areas. A staining score between 0 and 3 points was used in each zone, with the minimum and maximum total staining scores ranging between 0 and 15 points.0 is better. The degree of staining with Rose bengal dyes was scored as follows: 0 = no staining, 1= staining of less than half of the area, 2= staining of more than half of the area, 3= staining in the whole area.

Countries

Japan

Participant flow

Pre-assignment details

Informed consent was obtained from 332 patients, of whom 287 were randomized and prescribed the study drug.

Participants by arm

ArmCount
3% DE-089
3% DE-089 ophthalmic solution
144
0.1% HA
0.1% sodium hyaluronate ophthalmic solution
143
Total287

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event21
Overall StudyFear of adverse events01
Overall StudyLack of Efficacy02

Baseline characteristics

Characteristic3% DE-0890.1% HATotal
Age, Continuous55.3 years
STANDARD_DEVIATION 17.1
57.0 years
STANDARD_DEVIATION 16.8
56.1 years
STANDARD_DEVIATION 16.9
Sex: Female, Male
Female
120 Participants125 Participants245 Participants
Sex: Female, Male
Male
24 Participants18 Participants42 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
9 / 1441 / 143
serious
Total, serious adverse events
0 / 1441 / 143

Outcome results

Primary

Mean Change in Fluorescein Staining Score From Baseline

Fluorescein staining was scored according to the protocol by Shimmura et al. The cornea was divided into 3 equal zones: upper, middle, and lower. Each zone had a staining score ranging between 0 and 3 points, with minimum and maximum total staining scores ranging between 0 and 9 points. 0 is better. The degree of staining with Fluorescein dyes was scored as follows: 0 = no staining, 1= staining of less than half of the area, 2= staining of more than half of the area, 3= staining in the whole area.

Time frame: Baseline and 4-week (discontinued (LOCF))

Population: Efficacy analysis was performed full analysis set (FAS). In 0.1% sodium hyaluronate ophthalmic solution group, 1 subject was excluded from analysis because there was no available efficacy data in fluorescein staining.

ArmMeasureValue (MEAN)Dispersion
3% DE-089Mean Change in Fluorescein Staining Score From Baseline-2.12 pointsStandard Deviation 1.66
0.1% HAMean Change in Fluorescein Staining Score From Baseline-2.08 pointsStandard Deviation 1.52
95% CI: [-0.405, 0.338]l
Primary

Mean Change in Rose Bengal Staining Score From Baseline

Rose bengal staining were scored according to the protocol by Shimmura et al. The ocular surface was divided into 5 zones: nasal and temporal conjunctival, and upper, middle, and lower corneal areas. A staining score between 0 and 3 points was used in each zone, with the minimum and maximum total staining scores ranging between 0 and 15 points.0 is better. The degree of staining with Rose bengal dyes was scored as follows: 0 = no staining, 1= staining of less than half of the area, 2= staining of more than half of the area, 3= staining in the whole area.

Time frame: Baseline and 4-week (discontinued (LOCF))

Population: Efficacy analysis was performed full analysis set (FAS). In 0.1% sodium hyaluronate ophthalmic solution group, 2 subjects were excluded from analysis because there was no available efficacy data in rose bengal staining.

ArmMeasureValue (MEAN)Dispersion
3% DE-089Mean Change in Rose Bengal Staining Score From Baseline-3.06 pointsStandard Deviation 2.27
0.1% HAMean Change in Rose Bengal Staining Score From Baseline-2.38 pointsStandard Deviation 2.08
p-value: 0.0195% CI: [-1.18, -0.67]t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026